Bayer will showcase advancements from its comprehensive radiology portfolio at the European Congress of Radiology (ECR) 2026, scheduled to take place from March 4–8 in Vienna, Austria. The company’s presence will focus on progress in its contrast agent and injector development pipeline, alongside data-driven connectivity and informatics solutions aimed at enabling smarter workflows and more informed clinical decision-making in radiology.

A key highlight of Bayer’s scientific programme will be new clinical data from the development of gadoquatrane, an investigational low-dose macrocyclic gadolinium-based contrast agent for contrast-enhanced Magnetic Resonance Imaging (MRI). Bayer will present multiple Phase III subgroup analyses demonstrating the efficacy and safety of gadoquatrane in abdominal and cardiac MRI, Magnetic Resonance Angiography (MRA), as well as updated analyses from Phase II and III studies in Central Nervous System (CNS) imaging and pharmacokinetics.

Across its clinical development programme, gadoquatrane has been evaluated at a gadolinium dose of 0.04 mmol/kg body weight, representing a 60 percent reduction compared to standard macrocyclic gadolinium-based contrast agents dosed at 0.1 mmol/kg. The data presentations follow positive topline results announced in 2025 from all studies in the pivotal Phase III QUANTI programme.

Bayer has already submitted marketing authorisation applications for gadoquatrane in several major markets, including the US, EU, Japan and China, with additional submissions planned in the coming months.

Nelson Ambrogio, President of Radiology at Bayer, said, “ECR remains a key platform for scientific exchange and collaboration within the radiology community. Bayer is committed to advancing innovation and delivering technologies that support clinicians and improve patient outcomes worldwide.”

ECR 2026 Congress President Minerva Becker highlighted the importance of collaboration between academia and industry in advancing radiology, noting that Bayer’s contributions demonstrate how robust clinical science and technological innovation can translate into meaningful clinical impact.

With over a century of expertise in diagnostic imaging, Bayer continues to invest in contrast agents, imaging devices and informatics solutions across CT, MRI, X-ray and PET imaging. In 2024, Bayer’s radiology business generated Euro 2.1 billion in sales, reflecting its strong position in the global medical imaging market.